title: TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis.
abstract: Crohn's disease (CD) is a chronic, relapsing inflammatory bowel disease, characterized by transmural inflammation. In CD, the recurrent inflammatory injury and tissue repair that occurs in the intestine can progress uncontrollably, leading to the proliferation of mesenchymal cells as well as fibrosis, characterized by excessive extracellular matrix deposition. These processes thicken the bowel wall, reducing flexibility, and often culminate in obstructive strictures. Because no effective measures are currently available to specifically treat or prevent intestinal stricturing, we sought to gain a better understanding of its pathogenesis by developing a mouse model of intestinal fibrosis. Because transforming growth factor (TGF)-beta1 can mediate both fibrosis and mesenchymal cell proliferation; we studied the effects of delivering adenoviral vectors encoding spontaneously active TGF-beta1 into the colons of mice. We first demonstrated that enema delivery of marker adenoviral vectors led to the transfection of the colonic epithelium and transient transgene expression. Histologically, control vectors caused an acute inflammatory response, involving the recruitment of neutrophils and mononuclear cells into the colonic lamina propria; however, infection caused little if any fibrosis. In contrast, the TGF-beta1 vector caused a more severe and prolonged inflammatory response as well as localized collagen deposition, leading to severe and progressive fibrosis. This was accompanied by the emergence of cells with a myofibroblast phenotype. Ultimately the fibrosis resulted in many of the TGF-beta1-transfected mice developing profound colonic obstruction. Through adenoviral gene transfer technology, we describe a novel mouse model of colitis and implicate TGF-beta1 in the pathogenesis of obstructive intestinal fibrosis.
authors.affiliation: Division of Gastroenterology, British Columbia's Children's Hospital, Vancouver, British Columbia, Canada. bvallance@cw.bc.ca
authors.forename: Bruce A
authors.initials: BA
authors.lastname: Vallance
authors.forename: M Imelda
authors.initials: MI
authors.lastname: Gunawan
authors.forename: Bryan
authors.initials: B
authors.lastname: Hewlett
authors.forename: Premysl
authors.initials: P
authors.lastname: Bercik
authors.forename: Corinne
authors.initials: C
authors.lastname: Van Kampen
authors.forename: Francesca
authors.initials: F
authors.lastname: Galeazzi
authors.forename: Patricia J
authors.initials: PJ
authors.lastname: Sime
authors.forename: Jack
authors.initials: J
authors.lastname: Gauldie
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Collins
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D002492:Central Nervous System Depressants / Q000494:pharmacology; D003106:Colon / Q000276:immunology / Q000473:pathology* / Q000502:physiology*; D003424:Crohn Disease / Q000276:immunology / Q000473:pathology* / Q000503:physiopathology*; D004195:Disease Models, Animal; D004733:Enema; D004847:Epithelial Cells / Q000473:pathology; D000431:Ethanol / Q000494:pharmacology; D005347:Fibroblasts / Q000473:pathology; D005355:Fibrosis; D006801:Humans; D007413:Intestinal Mucosa / Q000276:immunology / Q000473:pathology; D007763:Lac Operon; D008156:Luciferases / Q000235:genetics; D008297:Male; D051379:Mice; D010641:Phenotype; D013047:Specific Pathogen-Free Organisms; D014162:Transfection; D016212:Transforming Growth Factor beta / Q000235:genetics*; D053773:Transforming Growth Factor beta1; D001616:beta-Galactosidase / Q000235:genetics
chemical_list: D002492:Central Nervous System Depressants; C508960:TGFB1 protein, human; C508961:Tgfb1 protein, mouse; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D000431:Ethanol; D008156:Luciferases; D001616:beta-Galactosidase